PARP inhibition in ovarian cancer: what is still missing?

IF 0.5 4区医学 Q4 OBSTETRICS & GYNECOLOGY

European journal of gynaecological oncology Pub Date : 2022-02-15 DOI:10.31083/j.ejgo4301016

M. Morotti, E. Ghisoni

引用次数: 0

Abstract

1Ludwig Institute for Cancer Research, Bâtiment AGORA, 1005 Lausanne, Switzerland 2Department of Gynecology, CHUV-Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland 3Department of Oncology, Immuno-Oncology Service, CHUV-Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland *Correspondence: drmorottimatteo@gmail.com (Matteo Morotti) Academic Editor: Enrique Hernandez Submitted: 11 October 2021 Revised: 16 November 2021 Accepted: 19 November 2021 Published: 15 February 2022

查看原文本刊更多论文

PARP在卵巢癌中的抑制作用:还缺少什么?

1卢德维格癌症研究所，Bâtiment AGORA，1005 Lausanne，Switzerland 2妇产科，瑞士洛桑1011 Vaudois大学CHUV中心医院3肿瘤科，免疫-肿瘤服务，瑞士洛桑101 Vaudoi大学CHUV中心医院*通讯：drmorottimatteo@gmail.com（Matteo Morotti）学术编辑：Enrique Hernandez提交：2021年10月11日修订：2021年11月16日接受：2021年12月19日发布：2022年2月15日

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European journal of gynaecological oncology 医学-妇产科学

自引率

25.00%

发文量

审稿时长

1 months

期刊介绍： EJGO is dedicated to publishing editorial articles in the Distinguished Expert Series and original research papers, case reports, letters to the Editor, book reviews, and newsletters. The Journal was founded in 1980 the second gynaecologic oncology hyperspecialization Journal in the world. Its aim is the diffusion of scientific, clinical and practical progress, and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists, and so on.